Eleven Biotherapeutics looks to raise almost $70M in IPO

|About: Eleven Biotherapeutics, Inc. (EBIO)|By:, SA News Editor

Eleven Biotherapeutics has filed to raise up to $69M in an IPO on Nasdaq, where it will trade under the EBIO ticker symbol.

Eleven Biotherapeutics develops a protein engineering platform called AMP-Rx for use in treating eye diseases.

The company was founded in 2008 and earned $1M in collaboration revenue in the year through September.